# Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

> **NCT02347865** · — · COMPLETED · sponsor: **Amgen** · enrollment: 777 (actual)

## Conditions studied

- Post Menopausal Osteoporosis

## Interventions

- **DRUG:** AMG 162 - Prolia
- **DRUG:** AMG 162 - Prolia

## Key facts

- **NCT ID:** NCT02347865
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-16
- **Primary completion:** 2017-10-26
- **Final completion:** 2018-09-27
- **Target enrollment:** 777 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347865, "Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02347865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*